Current List of Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 60449-60450 [2012-24212]

Download as PDF Federal Register / Vol. 77, No. 192 / Wednesday, October 3, 2012 / Notices Withdrawal of notice and request for comment. ACTION: The FDIC is withdrawing the Notice of Submission for OMB Review; Comment Request; Registration of Mortgage Loan Originators (3064–0171) published in the Federal Register on September 27, 2012 (77 FR 59397). The September 27, 2012 publication was an inadvertent duplication of the Notice of Submission for OMB Review; Comment Request; Registration of Mortgage Loan Originators (3064–0171) published in the Federal Register on September 26, 2012 (77 FR 59192). SUMMARY: Dated: September 27, 2012. Federal Deposit Insurance Corporation. Pamela Johnson, Regulatory Editing Specialist. [FR Doc. 2012–24277 Filed 10–2–12; 8:45 am] BILLING CODE 6714–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Current List of Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies Substance Abuse and Mental Health Services Administration, HHS. ACTION: Notice. AGENCY: The Department of Health and Human Services (HHS) notifies Federal agencies of the Laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809). A notice listing all currently certified Laboratories and Instrumented Initial Testing Facilities (IITF) is published in the Federal Register during the first week of each month. If any Laboratory/ IITF’s certification is suspended or revoked, the Laboratory/IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. erowe on DSK2VPTVN1PROD with SUMMARY: VerDate Mar<15>2010 15:03 Oct 02, 2012 Jkt 229001 If any Laboratory/IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter. This notice is also available on the Internet at https:// www.workplace.samhsa.gov and https:// www.drugfreeworkplace.gov. Mrs. Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, Room 2– 1042, One Choke Cherry Road, Rockville, Maryland 20857; 240–276– 2600 (voice), 240–276–2610 (fax). SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. The ‘‘Mandatory Guidelines for Federal Workplace Drug Testing Programs’’, as amended in the revisions listed above, requires strict standards that Laboratories and Instrumented Initial Testing Facilities (IITF) must meet in order to conduct drug and specimen validity tests on urine specimens for Federal agencies. To become certified, an applicant Laboratory/IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a Laboratory/IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections. Laboratories and Instrumented Initial Testing Facilities (IITF) in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A Laboratory/ IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/ NIDA) which attests that it has met minimum standards. In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following Laboratories and Instrumented Initial Testing Facilities (IITF) meet the minimum standards to conduct drug and specimen validity tests on urine specimens: FOR FURTHER INFORMATION CONTACT: Instrumented Initial Testing Facilities (IITF) None. Laboratories ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414–328–7840/800– 877–7016 (Formerly: Bayshore Clinical Laboratory). ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 585–429–2264. PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 60449 Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901–794–5770/888–290–1150. Aegis Analytical Laboratories, 345 Hill Ave., Nashville, TN 37210 615–255–2400 (Formerly: Aegis Sciences Corporation, Aegis Analytical Laboratories, Inc.). Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504–361–8989/800– 433–3823 (Formerly: Kroll Laboratory Specialists, Inc., Laboratory Specialists, Inc.). Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236, 804–378– 9130 (Formerly: Kroll Laboratory Specialists, Inc., Scientific Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.). Baptist Medical Center—Toxicology Laboratory, 11401 I–30, Little Rock, AR 72209–7056, 501–202–2783 (Formerly: Forensic Toxicology Laboratory Baptist Medical Center). Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215–2802, 800–445–6917. Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229–671–2281. DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA 18974, 215–674– 9310. ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 662–236–2609. Gamma-Dynacare Medical Laboratories*, A Division of the Gamma-Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519–679–1630. Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713–856–8288/800–800–2387. Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908–526– 2400/800–437–4986 (Formerly: Roche Biomedical Laboratories, Inc.). Laboratory Corporation of America Holdings, 1904 Alexander Drive, Research Triangle Park, NC 27709, 919–572–6900/800–833– 3984 (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group). Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671, 866–827–8042/800–233–6339 (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center). LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS 66219, 913–888– 3927/800–873–8845 (Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.,). Maxxam Analytics*, 6740 Campobello Road, Mississauga, ON, Canada L5N 2L8, 905– 817–5700 (Formerly: Maxxam Analytics Inc., NOVAMANN (Ontario), Inc.). MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112, 651–636– 7466/800–832–3244. MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503– 413–5295/800–950–5295. E:\FR\FM\03OCN1.SGM 03OCN1 60450 Federal Register / Vol. 77, No. 192 / Wednesday, October 3, 2012 / Notices erowe on DSK2VPTVN1PROD with Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612–725– 2088. National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661–322–4250/800–350–3515. One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504, 888–747–3774 (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory). Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311, 800–328– 6942 (Formerly: Centinela Hospital Airport Toxicology Laboratory). Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, WA 99204, 509–755–8991/800–541–7891x7. Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 858–643–5555. Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084, 800– 729–6432 (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline BioScience Laboratories). Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403, 610–631– 4600/877–642–2216 (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories). Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA 91304, 818– 737–6370 (Formerly: SmithKline Beecham Clinical Laboratories). South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 574–234–4176 x1276. Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177, Phoenix, AZ 85040, 602–438–8507/800–279–0027. STERLING Reference Laboratories, 2617 East L Street, Tacoma, Washington 98421, 800– 442–0438. Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 65203, 573–882–1273. US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., Fort George G. Meade, MD 20755–5235, 301–677–7085. *The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS’ NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP VerDate Mar<15>2010 15:03 Oct 02, 2012 Jkt 229001 may apply directly to the NLCP contractor just as U.S. laboratories do. Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 30, 2010 (75 FR 22809). After receiving DOT certification, the laboratory will be included in the monthly list of HHScertified laboratories and participate in the NLCP certification maintenance program. Janine Denis Cook, Chemist, Division of Workplace Programs, Center for Substance Abuse Prevention, SAMHSA. [FR Doc. 2012–24212 Filed 10–2–12; 8:45 am] BILLING CODE 4160–20–P DEPARTMENT OF HOMELAND SECURITY Office of the Secretary Senior Executive Service Performance Review Board Office of the Secretary, DHS. Notice correction. AGENCY: ACTION: This notice announces the appointment of the members of the Senior Executive Service Performance Review Boards for the Department of Homeland Security. The purpose of the Performance Review Board is to view and make recommendations concerning proposed performance appraisals, ratings, bonuses, pay adjustments, and other appropriate personnel actions for incumbents of Senior Executive Service, Senior Level and Senior Professional positions of the Department. DATES: Effective Dates: This Notice is effective October 3, 2012. FOR FURTHER INFORMATION CONTACT: Elizabeth Haefeli, Office of the Chief Human Capital Officer, telephone (202) 357–8164. SUPPLEMENTARY INFORMATION: Each federal agency is required to establish one or more performance review boards (PRB) to make recommendations, as necessary, in regard to the performance of senior executives within the agency. 5 U.S.C. 4314(c). This notice announces the appointment of the members of the PRB for the Department of Homeland Security (DHS). The purpose of the PRB is to review and make recommendations concerning proposed performance appraisals, ratings, bonuses, pay adjustments, and other appropriate SUMMARY: PO 00000 Frm 00078 Fmt 4703 Sfmt 4703 personnel actions for incumbents of SES positions within DHS. The Board shall consist of at least three members. In the case of an appraisal of a career appointee, more than half of the members shall consist of career appointees. Composition of the specific PRBs will be determined on an ad hoc basis from among the individuals listed below: Acton, John Alexander, Barbara Amparo, Alexis Anderson, Audrey J. Anderson, Gary L. Anderson, Rose J. Andrews, John Armstrong, Charles R. Athmann, Ronald Barber, Delores Baroukh, Nader Barrett, Lawerence Bartoldus, Charles Bathurst, Donald Bauhs, Kimberlyn J. Beagles, James Beckham, Steward D. Bedker, Larry Benda, Francis Paul Bernstein, Jarrod Bersin, Alan Bester, Margot Borkowski, Mark S. Borras, Rafael Boshears, Kevin Bourbeau, Sharie Boyce, Carla J. Boyce, Don R. Boyd, David Bray, Robert S. Brinsfield, Kathryn Brooks, Vicki Brown, Meddie Brown, Michael Brundage, William Brzymialkiewicz, Caryl Bucella, Donna A. Bucher, Steven P. Buckingham, Patricia A. Burke, Richard Butcher, Michael Button, Christopher Byrne, Michael F. Byrne, Sean J. Cahill, Donna L. Callahan, Colleen B. Cameron, Michael K. Canton, Lynn G. Cantor, Jonathan Carpenter, Dea D. Carson, Rebecca S. Carter, Gary Carusone, Pia Carwile III, William L. Castro, Raul Chaleki, Thomas Chaparro, James Chavez, Richard E:\FR\FM\03OCN1.SGM 03OCN1

Agencies

[Federal Register Volume 77, Number 192 (Wednesday, October 3, 2012)]
[Notices]
[Pages 60449-60450]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-24212]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Current List of Laboratories and Instrumented Initial Testing 
Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing 
for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of Health and Human Services (HHS) notifies 
Federal agencies of the Laboratories and Instrumented Initial Testing 
Facilities (IITF) currently certified to meet the standards of the 
Mandatory Guidelines for Federal Workplace Drug Testing Programs 
(Mandatory Guidelines). The Mandatory Guidelines were first published 
in the Federal Register on April 11, 1988 (53 FR 11970), and 
subsequently revised in the Federal Register on June 9, 1994 (59 FR 
29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); 
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and 
on April 30, 2010 (75 FR 22809).
    A notice listing all currently certified Laboratories and 
Instrumented Initial Testing Facilities (IITF) is published in the 
Federal Register during the first week of each month. If any 
Laboratory/IITF's certification is suspended or revoked, the 
Laboratory/IITF will be omitted from subsequent lists until such time 
as it is restored to full certification under the Mandatory Guidelines.
    If any Laboratory/IITF has withdrawn from the HHS National 
Laboratory Certification Program (NLCP) during the past month, it will 
be listed at the end and will be omitted from the monthly listing 
thereafter.
    This notice is also available on the Internet at https://www.workplace.samhsa.gov and https://www.drugfreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of 
Workplace Programs, SAMHSA/CSAP, Room 2-1042, One Choke Cherry Road, 
Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially 
developed in accordance with Executive Order 12564 and section 503 of 
Public Law 100-71. The ``Mandatory Guidelines for Federal Workplace 
Drug Testing Programs'', as amended in the revisions listed above, 
requires strict standards that Laboratories and Instrumented Initial 
Testing Facilities (IITF) must meet in order to conduct drug and 
specimen validity tests on urine specimens for Federal agencies.
    To become certified, an applicant Laboratory/IITF must undergo 
three rounds of performance testing plus an on-site inspection. To 
maintain that certification, a Laboratory/IITF must participate in a 
quarterly performance testing program plus undergo periodic, on-site 
inspections.
    Laboratories and Instrumented Initial Testing Facilities (IITF) in 
the applicant stage of certification are not to be considered as 
meeting the minimum requirements described in the HHS Mandatory 
Guidelines. A Laboratory/IITF must have its letter of certification 
from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met 
minimum standards.
    In accordance with the Mandatory Guidelines dated November 25, 2008 
(73 FR 71858), the following Laboratories and Instrumented Initial 
Testing Facilities (IITF) meet the minimum standards to conduct drug 
and specimen validity tests on urine specimens:

Instrumented Initial Testing Facilities (IITF)

    None.

Laboratories

ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-
328-7840/800-877-7016 (Formerly: Bayshore Clinical Laboratory).
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 
14624, 585-429-2264.
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, 
Memphis, TN 38118, 901-794-5770/888-290-1150.
Aegis Analytical Laboratories, 345 Hill Ave., Nashville, TN 37210 
615-255-2400 (Formerly: Aegis Sciences Corporation, Aegis Analytical 
Laboratories, Inc.).
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-
361-8989/800-433-3823 (Formerly: Kroll Laboratory Specialists, Inc., 
Laboratory Specialists, Inc.).
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236, 
804-378-9130 (Formerly: Kroll Laboratory Specialists, Inc., 
Scientific Testing Laboratories, Inc.; Kroll Scientific Testing 
Laboratories, Inc.).
Baptist Medical Center--Toxicology Laboratory, 11401 I-30, Little 
Rock, AR 72209-7056, 501-202-2783 (Formerly: Forensic Toxicology 
Laboratory Baptist Medical Center).
Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802, 
800-445-6917.
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229-
671-2281.
DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA 
18974, 215-674-9310.
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 
38655, 662-236-2609.
Gamma-Dynacare Medical Laboratories*, A Division of the Gamma-
Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT, 
Canada N6A 1P4, 519-679-1630.
Laboratory Corporation of America Holdings, 7207 N. Gessner Road, 
Houston, TX 77040, 713-856-8288/800-800-2387.
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, 
NJ 08869, 908-526-2400/800-437-4986 (Formerly: Roche Biomedical 
Laboratories, Inc.).
Laboratory Corporation of America Holdings, 1904 Alexander Drive, 
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984 
(Formerly: LabCorp Occupational Testing Services, Inc., CompuChem 
Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of 
Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A 
Member of the Roche Group).
Laboratory Corporation of America Holdings, 1120 Main Street, 
Southaven, MS 38671, 866-827-8042/800-233-6339 (Formerly: LabCorp 
Occupational Testing Services, Inc.; MedExpress/National Laboratory 
Center).
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS 
66219, 913-888-3927/800-873-8845 (Formerly: Quest Diagnostics 
Incorporated; LabOne, Inc.; Center for Laboratory Services, a 
Division of LabOne, Inc.,).
Maxxam Analytics*, 6740 Campobello Road, Mississauga, ON, Canada L5N 
2L8, 905-817-5700 (Formerly: Maxxam Analytics Inc., NOVAMANN 
(Ontario), Inc.).
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112, 
651-636-7466/800-832-3244.
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 
97232, 503-413-5295/800-950-5295.

[[Page 60450]]

Minneapolis Veterans Affairs Medical Center, Forensic Toxicology 
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088.
National Toxicology Laboratories, Inc., 1100 California Ave., 
Bakersfield, CA 93304, 661-322-4250/800-350-3515.
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, 
Pasadena, TX 77504, 888-747-3774 (Formerly: University of Texas 
Medical Branch, Clinical Chemistry Division; UTMB Pathology-
Toxicology Laboratory).
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 
91311, 800-328-6942 (Formerly: Centinela Hospital Airport Toxicology 
Laboratory).
Pathology Associates Medical Laboratories, 110 West Cliff Dr., 
Spokane, WA 99204, 509-755-8991/800-541-7891x7.
Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 858-
643-5555.
Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 
30084, 800-729-6432 (Formerly: SmithKline Beecham Clinical 
Laboratories; SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 
19403, 610-631-4600/877-642-2216 (Formerly: SmithKline Beecham 
Clinical Laboratories; SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA 
91304, 818-737-6370 (Formerly: SmithKline Beecham Clinical 
Laboratories).
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South 
Bend, IN 46601, 574-234-4176 x1276.
Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177, 
Phoenix, AZ 85040, 602-438-8507/800-279-0027.
STERLING Reference Laboratories, 2617 East L Street, Tacoma, 
Washington 98421, 800-442-0438.
Toxicology & Drug Monitoring Laboratory, University of Missouri 
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, 
MO 65203, 573-882-1273.
US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson 
St., Fort George G. Meade, MD 20755-5235, 301-677-7085.

    *The Standards Council of Canada (SCC) voted to end its Laboratory 
Accreditation Program for Substance Abuse (LAPSA) effective May 12, 
1998. Laboratories certified through that program were accredited to 
conduct forensic urine drug testing as required by U.S. Department of 
Transportation (DOT) regulations. As of that date, the certification of 
those accredited Canadian laboratories will continue under DOT 
authority. The responsibility for conducting quarterly performance 
testing plus periodic on-site inspections of those LAPSA-accredited 
laboratories was transferred to the U.S. HHS, with the HHS' NLCP 
contractor continuing to have an active role in the performance testing 
and laboratory inspection processes. Other Canadian laboratories 
wishing to be considered for the NLCP may apply directly to the NLCP 
contractor just as U.S. laboratories do.
    Upon finding a Canadian laboratory to be qualified, HHS will 
recommend that DOT certify the laboratory (Federal Register, July 16, 
1996) as meeting the minimum standards of the Mandatory Guidelines 
published in the Federal Register on April 30, 2010 (75 FR 22809). 
After receiving DOT certification, the laboratory will be included in 
the monthly list of HHS-certified laboratories and participate in the 
NLCP certification maintenance program.

Janine Denis Cook,
Chemist, Division of Workplace Programs, Center for Substance Abuse 
Prevention, SAMHSA.
[FR Doc. 2012-24212 Filed 10-2-12; 8:45 am]
BILLING CODE 4160-20-P